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Abstract. Objectives: Chemokines influence the migration of leukocytes to secondary lymphoid tissue and sites of inflammation.
In HIV patients, they are implicated in inflammatory complications of antiretroviral therapy (ART), notably Immune Reconsti-
tution Disease (IRD) and Sensory Neuropathy (SN). However most chemokines have not been monitored as patients begin ART
or correlated with IRD and SN.
Methods: Plasma chemokine levels were assessed longitudinally using commercial ELISAs in 69 patients treated in Kuala
Lumpur, Malaysia. Plasma was available at baseline and after 6, 12, 24 and 48 weeks on ART. Chemokine genotypes were
assessed using allele-specific fluorescent probes. IRD were diagnosed in 15 patients. 30 patients were screened for SN using the
ACTG BPNS tool after six months on ART. SN was detected in 8 patients.
Results: Plasma CXCL10 levels decreased on ART compared to baseline (p = 0.002–0.0001), but remain higher than healthy
controls (p  0.0001). The decline was clearer in patients without IRD. CCL5 levels rose on ART but remained similar to
controls. CCL2 levels were higher in patients than controls after week 12. Plasma chemokine levels were not affected by CD4+
T-cell counts or any genotypes tested. Several patients with SN displayed higher CCL5 levels throughout therapy compared to
patients without neuropathy. Levels of other chemokines and chemokine genotypes were not associated with SN.
Conclusions: Chemokines are differentially affected by ART. CXCL10 and CCL5 may influence IRD and CCL5 warrants further
investigation for an effect in SN. These trends are not influenced by chemokine genotypes investigated here.
Keywords: HIV sensory neuropathy, nucleoside analogue reverse transcriptase inhibitor sensory neuropathy, CCL5, CXCL10,
Immune Reconstitution Disease
1. Introduction
Antiretroviral therapy (ART) has improved life ex-
pectancy in HIV-infected individuals by suppressing
viral replication and reducing opportunistic infections.
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+61 618 9224 0204; E-mail: patricia.price@uwa.edu.au.
However, several adverse effects compromise both pa-
tient health and adherence to therapy. These include
Sensory Neuropathy (SN) [1] and Immune Reconsti-
tution Disease (IRD) [2,3]. Both are characterized by
dysregulated host inflammatory responses [4,5]. Cir-
culating chemokinesmay be a component of functional
immune reconstitution or may mediate SN or IRD.
Chemokines are critical for inflammation and the
induction of adaptive immune responses, but the effects
of ART on chemokines are not well characterized, and
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very few studies assess plasma chemokine levels in
longitudinal sample sets. Increased levels of CCL5
were evident from 4 weeks on ART in two studies [6,
7]. CCL5 production by cultured CD4+ and CD8+ T-
cells was associated with maintenance of undetectable
plasma HIV RNA for 1 year [8]. Plasma CXCL10
levels decreased after 24 weeks of ART in patients
from the USA and after 1 year on ART in Cambodian
patients [9,10]. Persistently high CXCL10 levels were
also associated with immunological treatment failure
following ART [11]. However other chemokines have
not beenmonitoredover time in patients initiatingART.
Up to 45% of HIV-1 infected patients experience an
IRD when numbers of memory CD4+ T-cells are ris-
ing on ART [3]. This parallels the restoration of im-
mune responses against pre-existing opportunistic in-
fections. The immune response may be immunopatho-
logical rather than protective (reviewed by Stone et
al. [12]). Pathogens commonly associated with IRD
include Mycobacterium avium, Mycobacterium tuber-
culosis, Cryptococcus neoformans, cytomegalovirus
(CMV), Hepatitis C virus (HCV), Hepatitis B virus
(HBV) and Varicella Zoster virus (VZV). Risk factors
for IRD include CD4+ T-cell counts below 50 cells/μL
prior to ART and an active or sub-clinical infection by
an opportunistic pathogen [2]. Chemokines are impli-
cated in IRD. Plasma levels of CXCL10, soluble (s)
CD30 (a marker of T-cell activation), CCL2 and IL-18
(a monokine required for T-cell activation)were all cor-
related with alaninetransaminase levels in 36 HBV co-
infected patients after 8 weeks on ART [13]. Increased
plasma levels of CXCL10 were associated with TB-
IRD in a cohort of 75 patients from Cambodia. When
considered together,highCXCL10, lowCCL2 and high
IL-18 levels before ART were significant predictors of
TB-IRD [9].
HIV and ART can cause peripheral SN [1]. Both SN
triggered by antiretroviral drugs [NRTI-SN] and HIV–
induced Distal Sensory Polyneuropathy (DSP) [14] are
characterised by pain and/or numbness in the feet,
typically with reduced ankle reflexes and/or sensory
signs [15]. DSP involves disordered inflammation,
with activated macrophages and cytokines (including
TNFα) observed around peripheral nerves in affected
patients [16,17] and inflammatory genotypes are impli-
cated in NRTI-SN [18]. There is also in vivo and in vit-
ro evidence that aberrant host inflammatory responses
underpin painful neuropathies in other settings [4].
This study addresses two questions. How does ART
affect circulating plasma chemokines and are these
changes reflected in the plasma of HIV patients with
ART-associated inflammatory diseases. The study is
based on a cohort of patients initiatingART in Malaysia
with advanced immunodeficiency and many oppor-
tunistic infections.
2. Materials and methods
2.1. Study subjects
Antiretroviral-naive HIV-infected patients attending
outpatient clinics at the University of Malaya Medical
Centre (Kuala Lumpur, Malaysia) were recruited for a
longitudinal study. All patients (n = 66) began ART
with CD4+ T-cell counts < 200/μl and donated plas-
ma at baseline, 6, 12, 24 and 48 weeks. Where all
data were available (n = 56), all patients achieved a
> 2-fold recovery of CD4+ T-cell count and/or CD4+
T-cells > 200/μl during ART. 28 healthy control sub-
jects from Kuala Lumpur donated blood once. DNA
was collected from peripheral blood neutrophils from
all participants. Laboratory, clinical and demograph-
ic data were collected from patients’ medical records.
The study was approved by the Ethics Committees of
the University of Malaya and informed consent was
obtained from all participants.
Fifteen patients experienced at least one IRD event,
including tuberculosis (TB; n = 7), Kaposi’s sarcoma
(n = 3), CMV (n = 3), dermatomal VZV (n = 1)
and cryptococcal meningitis (n = 1). IRD cases were
analysed together as the numbers are low. No co-
infection with HBV or HCV was reported.
Thirty patients were screened for neuropathy using
the AIDS Clinical Trials Group Brief Peripheral Neu-
ropathy Screening Tool (ACTG BPNS) [19] at least 6
months after commencing ART. SN was defined by the
presence of both symptoms and signs on the ACTG
BPNS.
2.2. Sample collection and CD4+ T-cell counts
EDTA-treated blood was collected from patients at
baseline and weeks 6, 12, 24 and 48. Peripheral blood
mononuclear cells were isolated by Ficoll gradient cen-
trifugation and plasma and neutrophils were stored at
−80◦C. CD4+ T-cell counts were measured in EDTA-
treated whole blood by routine flow cytometry.
2.3. Quantification of chemokines in plasma
Plasma CCL5 was quantitated using DuoSet ELISA
(R&D systems, Minneapolis) and CCL2 and CXCL10
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were quantitated using BDOptEIA ELISA (BDBio-
sciences). Absorbance was read at 450nm and Mi-
croplate Manager software (version 5.2; Bio-Rad) was
used for analysis. The lowest limits of detection for
the CCL5, CCL2 and CXCL10 assays were 15, 1 and
5 pg/mL, respectively.
2.4. DNA extraction and SNP genotyping
DNA was extracted from blood neutrophils using a
QIAamp DNA Blood Mini Kit (QIAGEN; Valencia,
CA) and stored at−80◦C. Eleven SNP were genotyped
using Taqman FAM or VIC-labelled probes [C 1587
4407 10; rs2107538 (CCL5), C 15944115 20; rs2069
705 (IFNγ), C 27478341 10; rs3760396 (CCL2), C
15874396 20; rs2280788 (CCL5), C 11939405 1 ;
rs4586 (CCL2), C 7449817 10; rs1024610 (CCL2),
C 1085600 10; rs1799945 (HFE), C 9546517 10;
rs1143634 (IL1B), C 1839943 10; rs16944 (IL1B),
C 2590362 10; rs1024611 (CCL2),C 1085595 10;
rs1800562 (HFE)] andUniversal PCRMasterMix (Ap-
plied Biosystems; Foster City, CA). Aliquots of 10ng
were dried down on 384-well microtiter plates and am-
plified on a Roche LC480 (Roche Applied Science;
Indianapolis, IN). Thermocycling used one step of 10
min at 95◦C followed by 40 cycles of denaturation at
92◦C for 15s with annealing and extension at 60◦C
for 1 min. Fluorescence was read on a Roche LC480
using proprietary allelic discrimination software. Re-
peats and non-template controls were included in each
run. The median (range) genotyping success rates were
99 (98–100) % for each SNP in all cohorts.
3. Statistical analysis
Plasma chemokine data were assessed using the
Graphpad Software Package (Graphpad Software Inc;
San Diego, CA) and Stata version 10.1 (StataCorp,
College Station, Texas, USA). Demographic details,
plasma chemokine levels and minor allele carriage
were compared between groups using Chi2 or Fisher’s
Exact tests (dichotomous variables), Wilcoxon rank-
sum or Mann-Whitney paired tests [non-normally dis-
tributed continuous variables]. Correlations between
chemokine levels and time on ART were assessed us-
ing linear regression modelling, clustered by patient
to account for multiple measures from each individu-
al. Chemokine levels were log transformed to approx-
imate normality. Correlations between chemokine lev-
els and CD4+ T-cell counts were analysed using Spear-
man’s test, [non-normally distributed continues vari-
ables]. Allele and genotype frequencies in each eth-
nic group conformed with Hardy-Weinberg equilibri-
um (HWE) when assessed using GENEPOP v3.3 [20].
4. Results
4.1. Time on ART influences chemokine levels in a
longitudinal cohort
The effects of ART on plasma chemokine levels are
shown in Fig. 1. CXCL10 levels were lower after
6 weeks on ART compared to baseline (p = 0.002–
< 0.0001; Wilcoxon rank-sum), but remained higher
than healthy controls (p  0.0001; Mann Whitney).
The association between decreasing log CXCL10 lev-
els and time on ART was confirmed using a linear re-
gression model clustered by patient (p  0.0001, r2 =
0.18) (Fig. 1a).
Plasma CCL5 levels rose slowly during ART and
were higher than baseline from week 6 to week 48 (p =
0.04–0.006; Wilcoxon rank-sum). However, plasma
levels of CCL5 measured in HIV patients (either at
baseline or during ART) were similar to healthy con-
trols (p  0.1; Mann Whitney) (Fig. 1b).
Levels of CCL2 were below the limit of detection
in most samples, so we saw no clear trends over time.
However, CCL2 was detectable in 101 of 324 (31%) of
samples from HIV patients, compared with only 5 of
38 (13%) from controls (p = 0.02; Chi2 test). CCL2
levels were higher in HIV patients than controls at all
time points from week 12 (p = 0.04–p = 0.01; Mann
Whitney) (Fig. 1c).
A rise in CD4+ T-cell counts with time on ART was
evident in the entire cohort as expected (Fig. 1d). We
found no associations between CD4+ T-cell recovery
and plasma levels of any chemokine measured here
(p = 0.63–0.92; Mann Whitney). Baseline CD4+ T-
cell countswere also not predictive of chemokine levels
(r = −0.007–0.17, p = 0.1–0.8; Spearmen’s test).
4.2. Plasma levels of CXCL10 and CCL5 are elevated
in IRD patients
Plasma CXCL10 levels fell by week 6 compared to
baseline levels in patients with no IRD (p = 0.001;
Wilcoxon-rank sum), but did not decline significantly
in IRD patients (p = 0.09–0.8) (Fig. 2a).
Plasma CCL5 concentrations were similar to control
donors in patients without IRD (p  0.2 at all time
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Fig. 1. Chemokine levels and CD4+ T-cell counts over time in HIV patients initiating ART. The x axis shows number of weeks on ART. The y
axis indicates plasma concentrations of (a) CXCL10, (b) CCL5 and (c) CCL2, and (d) CD4+ T-cell count. ∗p  0.05; ∗∗p  0.01; ∗∗∗p 
0.001.
points tested; Mann Whitney) but higher than controls
in IRD patients. This difference was significant at
weeks 6, 12 and 48 (p = 0.03, p = 0.0004, p = 0.003
respectively) (Fig. 2b).
4.3. Plasma levels of CCL5 are high in some patients
with SN
This study had limited power to explore associations
between HIV-SN and plasma chemokine levels, with
only 30 patients screened for SN. However three of 8
patients with SN displayed persistently elevated plasma
levels of CCL5 on ART (Fig. 3). This was not apparent
in any of the 22 patients without SN (p = 0.01; Fisher’s
test). The finding warrants further consideration in
larger cohorts where SN status is followed at baseline
as well as during ART. Patterns of plasma CCL2 and
CXCL10 over time were similar in HIV patients with
and without SN.
4.4. Chemokine Genotyping
A panel of SNPs in the CCL5, CCL2 and IFNγ genes
was chosen based on reported associations with plas-
ma chemokine levels or inflammatory diseases. Al-
lele and genotype frequencies in each ethnic group
conformed with Hardy-Weinberg equilibrium (HWE)
when assessed using GENEPOP v3.3 [20]. No associ-
ations were observed between SNPs and CD4+ T cell
recovery, the development of SN or an IRD, or plas-
ma chemokine levels – other than a modest associa-
tion between increased baseline plasma CXCL10 and
carriage of rs1024610 minor allele (p = 0.05; Fisher’s
test). This association may be random as the SNP is in
CCL2. No association was observed between baseline
CD4+ T cell counts and any of the tested SNPs (p =
0.06–0.8; Fisher’s test)
5. Discussion
This study assessed changes in plasma chemokine
levels in a longitudinal study of patients beginningART
with advanced HIV disease. CXCL10 levels fell on
ART, consistent with our findings in a Cambodian co-
hort [9]. However CXCL10 levels remain higher in
Malaysian HIV patients at all time points compared to
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(a)
(b)
Fig. 2. Chemokine levels over time in patients initiating ART in patients who did (red) and did not (blue) develop an IRD. The x axis indicates
weeks on ART. The y axis indicates plasma concentrations of (a) CXCL10 and (b) CXCL5. ∗p  0.05; ∗∗p  0.01; ∗∗∗p  0.001.
healthy controls. Importantly CXCL10 levels did not
decline to the same extent in IRD patients despite 48
weeks of effective ART. This has been described in TB
IRD [9] and HBV IRD [13]. CXCL10 is induced by
IFNγ, and is responsible for recruiting T-cells to sites
of inflammation and activation of NK cells. The persis-
tently elevated levels of CXCL10 observed in patients
with IRD may contribute to the inflammation charac-
teristic of IRD.
In contrast to CXCL10, CCL5 levels rose as patients
responded to ART but did not differ significantly from
healthy controls. It is also notable that the increase in
CCL5 plasma levels during ART is less than the de-
crease of CXCL10 levels in patients on ART, indicat-
ing that CXCL10 is possibly a more useful monitor of
patient response to ART. Elevated plasma CCL5 levels
were seen in 3 out of 8 patients who experienced SN,
but not in ART-treated patients without SN. It is plausi-
ble that elevated CCL5 may contribute to the develop-
ment of SN in some patients, with in vitro studies in cul-
tured dorsal root ganglia (DRG) finding CCL5-CCR5
ligation created neurotoxicity similar to that induced
by gp-120 [21]. Moreover administration of CCL5 to
adult rat hind paw produced dose-dependent tactile al-
lodynia [22]. CCL5 can promote production of the
pro-inflammatory cytokine TNFα in co-culture [23],
possibly leading to TNFR1-mediated neurotoxicity and
resulting neuropathy.
Plasma CCL2 was frequently below the limit of de-
tection for our assay. Nonetheless, detectable CCL2
was more common in patients than controls, so this
chemokine warrants further investigation. Detectable
levels of plasma CCL2 were not associated with IRD
or SN. CCL2 inhibits viral entry in peripheral blood
lymphocytes via competitive binding of the CCR2 and
CCR5 receptors [24,25]. CCL2 is produced in re-
sponse to pro-inflammatory stimuli and attracts mono-
cytes, macrophages, basophils, mast cells, T lympho-
cytes, natural killer cells and dendritic cells to sites of
injury [26]. This range of effects illustrates the com-
plexity that needs to be considered in future studies.
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Fig. 3. Plasma concentrations of CCL5 in (a) individual patients with sensory neuropathy and (b) patients without neuropathy.
No genotypes tested affected chemokine levels or
disease status. The panel of SNPs were selected from
published papers [27–34]. All were associated with
inflammatory disorders or with a change in chemokine
levels in vivo or in vitro. Several IRD have been asso-
ciated with low baseline CD4+ T-cell counts (summa-
rized in [35]) and with steady high levels of CXCL10
on ART [9,13]. Hence we examined whether high lev-
els of CXCL10 were a feature of low baseline counts.
However we found no association between CXCL10
levels and CD4+ T-cell counts at any time before or
during treatment.
There were several limitations to our study. Firstly,
as this was a preliminary study, the cohort was small,
patients with any IRD were assessed together – using
the hypothesis that all IRD represent an immunopathol-
ogy [36]. However different mechanisms may mediate
IRD associated with different pathogens [3], so future
studies should assess these separately. Similarly the
study was not adequately powered to explore associa-
tions between chemokine levels and SN, highlighting
the need for a larger cohort. Future studies should also
include assessments of immune activation and assess-
ment of SN status prior to ART (to assist in distinguish-
ing DSP from cases of SN developing on ART).
In summary; plasma levels of CXCL10 decreased
and CCL5 increased during ART. CCL2 levels were
elevated by HIV disease, but did not change on ART.
Patients reporting an IRD maintained high levels of
CXCL10 compared to non IRD patients, Some patients
with SN displayed elevated levels of CCL5 on ART
indicating that altered chemokines levels are possibly
one of a multitude of factors contributing to aetiology of
this condition. Chemokine levels were not associated
withCD4+T-cell counts before and onART. These data
suggest that chemokines play a role in the inflammatory
pathways of IRD and SN, but do not support a role
for the chemokines studied in CD4+ T-cell recovery on
ART.
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